Event Description
Prof. Roberts discussed how the FDA's approval of the first race-specific drug has generated a heated debate about the scientific and political efficacy of race-based medicine. She placed this debate in the context of health disparities and genetic concepts of race, and explored why marketing pharmaceuticals on the basis of race is more likely to worsen racial inequities than cure them. Recognizing that race-based medicine raises both medical and political questions, Roberts rejected the dichotomy often claimed by its promoters that we must put aside social justice concerns in order to improve minority health.
Read the related article from the Minnesota Journal of Law, Science & Technology.
Commentators
Jay Cohn, MD
Professor of Medicine, Cardiovascular Division
Director, Rasmussen Center for Cardiovascular Disease Prevention
University of Minnesota
Joycelyn Dorscher, MD
Assistant Professor, Family Medicine
University of Minnesota-Duluth
Sponsorship
The Deinard Memorial Lecture on Law & Medicine is co-sponsored by the University of Minnesota's Joint Degree Program in Law, Health & the Life Sciences and the Center for Bioethics.
Support for the series comes from the law firm of Leonard Street and Deinard and the Deinard family.
Continuing Education Information
Continuing legal education credit (CLE) for attorneys (1.5 hours) has been approved.
The University of Minnesota is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Application was approved for AMA PRA Category 1 Credit.